See Graham's ranking
4.0
Sanofi is a corporation listed on Nasdaq under the ticker SNY, operating in the healthcare sector and within the global pharmaceutical subsector. Its original formation involved French executives and researchers connected to the chemical and biomedical industries, with an initial focus on developing innovative medicines and therapeutic solutions for chronic and emerging diseases.
The portfolio includes prescription pharmaceuticals, vaccines, specialty therapies, treatments for rare diseases, immunology, oncology, diabetes and cardiovascular products. Operations encompass clinical research, biotechnology development, large-scale industrial manufacturing, and international distribution.
The company’s market presence is global, with consolidated operations across Europe, North America, Latin America, Africa and Asia. Its products serve hospitals, clinics, public health networks, distributors, pharmacies and government organizations responsible for immunization programs and access to essential medicines.
Market drivers include healthcare regulation, competition with multinational pharmaceutical companies, research and development costs, patent cycles, public health policies, demand for biologic therapies, biotechnology trends and pricing practices in both developed and emerging markets.
Operational scale consists of dozens of manufacturing facilities, research laboratories, biotechnology centers and logistics hubs across multiple continents. The structure includes thousands of employees and delivers medicines to millions of patients annually through global commercial networks.
The operational framework comprises headquarters in France, regional subsidiaries, innovation centers, production divisions and units dedicated to vaccines, specialty therapies and traditional pharmaceuticals. Logistics processes include cold-chain distribution, specialized storage, regulated transportation and digital tracking systems.
The operating model is based on pharmaceutical innovation, clinical development, regulated industrial production, global distribution and strategic partnerships with research institutions and healthcare organizations. Production chains follow international standards of quality, safety and regulatory compliance.
Its shares are traded exclusively on Nasdaq under the ticker SNY.
History and foundation
Founded in 1973 in Paris, Sanofi originated from the reorganization of industrial assets within the French chemical sector, with the objective of enhancing international competitiveness and consolidating the development of strategic medicines.The early years involved challenges related to establishing production lines, expanding pharmaceutical portfolios and integrating companies from the biomedical industry. Initial achievements included advancements in metabolic therapy research and the creation of commercial networks across Europe.
The expansion phase unfolded over the subsequent decades, marked by entry into new global markets, diversification of therapeutic areas, vaccine development and strengthened investment in biotechnology. This growth solidified its presence in segments with significant clinical demand.
Key historical milestones include the offer pública inicial (IPO) conducted in 1973, strategic mergers and acquisitions such as the incorporation of Aventis in 2004, and the expansion of its vaccine division through Sanofi Pasteur. Pipeline modernization and the creation of units dedicated to rare diseases also marked important stages.
Between 2020 and 2024, notable developments included progress in immunology therapies, increased investment in biotechnology, strategic adjustments to mature drug portfolios, internal reorganizations, vaccine-related advancements and impacts from macroeconomic volatility affecting input costs and global demand dynamics.
Additional Information
The Company Sanofi (United States), is listed on Nasdaq with a market value of $ 118.21 Billions, having an equity of $ 81.06 Billions.
With a total of 99.412 employees, the company is listed in the sector of Health and categorized in industry of Pharmaceutical Products.
In the last 12 months the Company had a revenue of $ 75.98 Billions, which generated a profit in the amount of $ 11.27 Billions.
As for its main indicators, the Company has a P/E ratio of 10.49, a P/BV ratio of 1.46 and in the last 12 months the dividend yield of SNY was at 4.59%.
The Company is traded internationally through the ticker SNY.
